Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
NASDAQ:OCGN
OCGN Stock Chart & Stats
$1.51
-$0.04(-4.99%)
At close: 4:00 PM EST
$1.51
-$0.04(-4.99%)
Day’s Range― - ―
52-Week Range$0.52 - $1.96
Previous CloseN/A
Volume1.89M
Average Volume (3M)4.99M
Market Cap
$468.88M
Enterprise Value$494.65M
Total Cash (Recent Filing)$32.56M
Total Debt (Recent Filing)$32.96M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Mar 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding327,888,370
10 Day Avg. Volume5,130,386
30 Day Avg. Volume4,987,645
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)7.36
Price to Sales (P/S)53.80
P/FCF Ratio-4.79
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue92.11
Enterprise Value/Gross Profit92.11
Enterprise Value/Ebitda-8.60
Forecast
1Y Price Target
$7.67Price Target Upside407.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$3.85M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyMid-stage trial showed a statistically significant slowing of geographic atrophy lesion growth and preservation of an anatomical biomarker linked to photoreceptor function, suggesting potential meaningful vision benefits versus placebo.
Financing And Regulatory RunwayCompleted equity financing plus accelerating enrollment in pivotal studies supports an extended development runway and positions the company to pursue multiple BLA filings beginning in 2026.
Safety And DeliveryAnalyst notes a clean safety profile with no reported intraocular inflammation or retinal detachment and highlights a durable subretinal delivery that could reduce the burden and infection risks of frequent intravitreal injections.
Bears Say
Execution And Intellectual Property RiskAnalyst warns that commercial execution, clinical setbacks, partnership dynamics, financial constraints, and intellectual property challenges could impede reaching the price target and slow product launch plans.
Market SentimentShares trading down to the offering price reflect market skepticism that could pressure the stock despite encouraging clinical data.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.52 and its highest was $1.96 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $468.88M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Mar 27, 2026 which is in 50 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Nov 05, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.056 by -$0.014.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 327,888,370 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.056. Following the earnings report the stock price went down -1.399%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (407.95% Upside)
$7.67 (407.95% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.6%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.72%
12-Months-Change
Fundamentals
Return on Equity
-289.93%
Trailing 12-Months
Asset Growth
-7.01%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
OCGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in gene therapy programs and strategic partnerships, alongside promising clinical data. However, the company faced increased operating expenses and a decline in cash position. Overall, the positive advancements and strategic positioning contribute to an optimistic outlook.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$7.67
▲(407.95% Upside)
Technical Analysis
Ownership Overview
2.64% Insiders
5.35% Mutual Funds
0.11% Other Institutional Investors
86.37% Public Companies and Individual Investors